tofacitinib
Sponsor Pfizer INC · listed as PFE
READOUT
Phase 3
Confidence: medium
Source: clinicaltrials
tofacitinib is a clinical-stage drug asset sponsored by Pfizer INC, listed as PFE. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Apr 14, 2027 (day precision, medium confidence), tied to trial NCT04624230. The asset is in Phase 3 and currently active not recruiting, studied in Ulcerative Colitis. It appears across 2 tracked trials in the CSA sample.
Next catalyst
Event typeREADOUT
Expected date2027-04-14
As disclosedApr 14, 2027
Date precisionday
Confidencemedium
Trial & sponsor
Trial (NCT)NCT04624230
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorPfizer
Listed asPFE
Condition(s)Ulcerative Colitis
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.
Get the full dataset — $499 → More PFE catalysts